Related Experiment Video

Updated: Sep 26, 2026

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates
09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

Potential for proteasome inhibition in the treatment of cancer

Julian Adams1

  • 1Millennium Pharmaceuticals, 35 Landsdowne Street, Cambridge, MA 02139, USA. jadams@mpi.com

Drug Discovery Today
|March 26, 2003
PubMed

Insights

Peptide boronates, like bortezomib, offer a promising new cancer treatment by inducing cancer cell death. Early trials show bortezomib is safe and effective, with ongoing studies confirming its therapeutic potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Proteasome inhibition represents a novel strategy for cancer therapy.
  • Most proteasome inhibitors face challenges in clinical development.
  • Peptide boronates offer an advancement over earlier proteasome inhibitors.

Purpose of the Study:

  • To introduce bortezomib (VELCADE; formerly PS-341) as a novel peptide boronate proteasome inhibitor.
  • To summarize preclinical and clinical findings for bortezomib.
  • To evaluate the therapeutic potential and safety of bortezomib in cancer treatment.

Main Methods:

  • Preclinical studies assessed bortezomib's antitumor activity across various tumor types.
  • Phase I clinical trials evaluated bortezomib's safety and tolerability.
  • A twice-weekly dosing regimen was identified and is under investigation.

Main Results:

  • Bortezomib demonstrated significant antitumor activity in preclinical models.
  • Phase I trials indicated manageable toxicity profiles.
  • A twice-weekly dosing schedule was supported by initial clinical data.

Conclusions:

  • Bortezomib is a clinically viable peptide boronate proteasome inhibitor.
  • The drug exhibits promising antitumor effects and a manageable safety profile.
  • Ongoing Phase III studies are further evaluating bortezomib's efficacy.

More Related Videos

A Fluorescence-based Protocol for Preliminary Screening of Protein Synthesis Inhibitors from Natural Sources10:24

A Fluorescence-based Protocol for Preliminary Screening of Protein Synthesis Inhibitors from Natural Sources

Published on: January 27, 2026

Cell-Based Drug Screening for Inhibitors of Autophagy Related 4B Cysteine Peptidase09:51

Cell-Based Drug Screening for Inhibitors of Autophagy Related 4B Cysteine Peptidase

Published on: June 30, 2023

Related Concept Videos

The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...